{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T14:13:13Z","timestamp":1760710393376},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,10]],"date-time":"2020-11-10T00:00:00Z","timestamp":1604966400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,11,10]],"date-time":"2020-11-10T00:00:00Z","timestamp":1604966400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s40120-020-00219-y","type":"journal-article","created":{"date-parts":[[2020,11,10]],"date-time":"2020-11-10T10:03:17Z","timestamp":1605002597000},"page":"149-167","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Consequences of Insurance Denials Among U.S. Patients Prescribed Repository Corticotropin Injection for Acute Exacerbations of Multiple Sclerosis"],"prefix":"10.1007","volume":"10","author":[{"given":"J. Bradford","family":"Rice","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary P.","family":"Panaccio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan","family":"White","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Simes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma","family":"Billmyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathaniel","family":"Downes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Niewoehner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George J.","family":"Wan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,11,10]]},"reference":[{"issue":"10","key":"219_CR1","doi-asserted-by":"publisher","first-page":"e1029","DOI":"10.1212\/wnl.0000000000007035","volume":"92","author":"MT Wallin","year":"2019","unstructured":"Wallin MT, Culpepper WJ, Campbell JD, et al. The prevalence of MS in the United States. Neurology. 2019;92(10):e1029\u201340. https:\/\/doi.org\/10.1212\/wnl.0000000000007035.","journal-title":"Neurology"},{"issue":"2","key":"219_CR2","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1212\/wnl.58.2.169","volume":"58","author":"DS Goodin","year":"2002","unstructured":"Goodin DS, Frohman EM, Garmany GP Jr, et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology. 2002;58(2):169\u201378. https:\/\/doi.org\/10.1212\/wnl.58.2.169.","journal-title":"Neurology."},{"key":"219_CR3","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.msard.2018.09.002","volume":"26","author":"T Nazareth","year":"2018","unstructured":"Nazareth T, Rava AR, Polyakov JL, et al. Relapse prevalence, symptoms, and health care engagement: patient insights from the Multiple Sclerosis in America 2017 survey. Multiple sclerosis and related disorders. 2018;26:219\u201334. https:\/\/doi.org\/10.1016\/j.msard.2018.09.002.","journal-title":"Multiple sclerosis and related disorders."},{"key":"219_CR4","unstructured":"Types of MS National Multiple Sclerosis Society; 2020. https:\/\/www.nationalmssociety.org\/What-is-MS\/Types-of-MS. Accessed 19 June 2020."},{"issue":"5","key":"219_CR5","doi-asserted-by":"publisher","first-page":"e0231846","DOI":"10.1371\/journal.pone.0231846","volume":"15","author":"C Ohlmeier","year":"2020","unstructured":"Ohlmeier C, Gothe H, Haas J, et al. Epidemiology, characteristics and treatment of patients with relapsing remitting multiple sclerosis and incidence of high disease activity: real world evidence based on German claims data. PLoS ONE. 2020;15(5):e0231846. https:\/\/doi.org\/10.1371\/journal.pone.0231846.","journal-title":"PLoS ONE"},{"key":"219_CR6","unstructured":"Relapse Management: National Multiple Sclerosis Society; 2020 [cited 2020 June 19]. https:\/\/www.nationalmssociety.org\/Treating-MS\/Managing-Relapses."},{"issue":"11","key":"219_CR7","doi-asserted-by":"publisher","first-page":"e0188644","DOI":"10.1371\/journal.pone.0188644","volume":"12","author":"S Liu","year":"2017","unstructured":"Liu S, Liu X, Chen S, et al. Oral versus intravenous methylprednisolone for the treatment of multiple sclerosis relapses: a meta-analysis of randomized controlled trials. PLoS One. 2017;12(11):e0188644. https:\/\/doi.org\/10.1371\/journal.pone.0188644.","journal-title":"PLoS One"},{"key":"219_CR8","doi-asserted-by":"publisher","unstructured":"Burton JM, O\u2019Connor PW, Hohol M, et al. Oral versus intravenous steroids for treatment of relapses in multiple sclerosis. Cochrane Datab Syst Rev 2009;8(3):Cd006921. https:\/\/doi.org\/10.1002\/14651858.cd006921.pub2.","DOI":"10.1002\/14651858.cd006921.pub2"},{"issue":"8","key":"219_CR9","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1080\/03007995.2018.1474090","volume":"34","author":"JB Rice","year":"2018","unstructured":"Rice JB, White AG, Johnson M, et al. Quantitative characterization of the relationship between levels of extended corticosteroid use and related adverse events in a US population. Curr Med Res Opin. 2018;34(8):1519\u201327. https:\/\/doi.org\/10.1080\/03007995.2018.1474090.","journal-title":"Curr Med Res Opin"},{"issue":"9","key":"219_CR10","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1080\/13696998.2018.1474750","volume":"21","author":"JB Rice","year":"2018","unstructured":"Rice JB, White AG, Johnson M, et al. Healthcare resource use and cost associated with varying dosages of extended corticosteroid exposure in a US population. J Med Econ. 2018;21(9):846\u201352. https:\/\/doi.org\/10.1080\/13696998.2018.1474750.","journal-title":"J Med Econ."},{"issue":"11","key":"219_CR11","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1016\/j.clinthera.2017.09.011","volume":"39","author":"JB Rice","year":"2017","unstructured":"Rice JB, White AG, Scarpati LM, et al. Long-term systemic corticosteroid exposure: a systematic literature review. Clin Ther. 2017;39(11):2216\u201329. https:\/\/doi.org\/10.1016\/j.clinthera.2017.09.011.","journal-title":"Clin Ther"},{"key":"219_CR12","unstructured":"Treating multiple sclerosis relapses: multiple sclerosis Association of America; 2020 [cited 2020 June 19]. http:\/\/www.mymsaa.org\/ms-information\/treatments\/relapses."},{"issue":"2","key":"219_CR13","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1097\/WNF.0b013e31820a17f3","volume":"34","author":"I Elovaara","year":"2011","unstructured":"Elovaara I, Kuusisto H, Wu X, et al. Intravenous immunoglobulins are a therapeutic option in the treatment of multiple sclerosis relapse. Clin Neuropharmacol. 2011;34(2):84\u20139. https:\/\/doi.org\/10.1097\/WNF.0b013e31820a17f3.","journal-title":"Clin Neuropharmacol"},{"key":"219_CR14","unstructured":"Acthar Prescribing Information: Mallinckrodt Pharmaceuticals 2019 [cited 2020 June 19]. Available from: https:\/\/www.acthar.com\/pdf\/Acthar-PI.pdf."},{"key":"219_CR15","doi-asserted-by":"publisher","unstructured":"Rose A, Kuzma JW, Kurtzke JF, et al. Cooperative study in the evaluation of therapy in multiple sclerosis: ACTH vs. placebo\u2014final report. Neurology. 1970;20(5 Part 2):1\u201359. https:\/\/doi.org\/10.1212\/wnl.20.5_part_2.1.","DOI":"10.1212\/wnl.20.5_part_2.1"},{"key":"219_CR16","doi-asserted-by":"publisher","first-page":"381","DOI":"10.2147\/dddt.S19331","volume":"5","author":"JP Simsarian","year":"2011","unstructured":"Simsarian JP, Saunders C, Smith DM. Five-day regimen of intramuscular or subcutaneous self-administered adrenocorticotropic hormone gel for acute exacerbations of multiple sclerosis: a prospective, randomized, open-label pilot trial. Drug Des Dev Ther. 2011;5:381\u20139. https:\/\/doi.org\/10.2147\/dddt.S19331.","journal-title":"Drug Des Dev Ther."},{"key":"219_CR17","doi-asserted-by":"publisher","first-page":"247","DOI":"10.2147\/btt.S53007","volume":"7","author":"K Damal","year":"2013","unstructured":"Damal K, Stoker E, Foley JF. Optimizing therapeutics in the management of patients with multiple sclerosis: a review of drug efficacy, dosing, and mechanisms of action. Biol Targ Ther. 2013;7:247\u201358. https:\/\/doi.org\/10.2147\/btt.S53007.","journal-title":"Biol Targ Ther."},{"key":"219_CR18","unstructured":"Kunker KA, Drake AS, Irwin LN, et al. Cognitive changes in multiple sclerosis patients treated with subcutaneous adrenocorticotropic hormone for acute relapse [Abstract P1111]. ECTRIMS Online Library. 2016."},{"key":"219_CR19","doi-asserted-by":"crossref","unstructured":"Nazareth T, Datar M, Sheer R, et al. MS relapse treatments and relapse resolution: retrospective study results from a US health plan [ECTRIMS-ACTRIMS poster P809]. ECTRIMS Online Library. 2017.","DOI":"10.26226\/morressier.59a3eda9d462b8028d89594a"},{"issue":"2","key":"219_CR20","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s40120-019-00156-5","volume":"8","author":"T Nazareth","year":"2019","unstructured":"Nazareth T, Datar M, Yu TC. Treatment effectiveness for resolution of multiple sclerosis relapse in a US Health Plan Population. Neurol Ther. 2019;8(2):383\u201395. https:\/\/doi.org\/10.1007\/s40120-019-00156-5.","journal-title":"Neurol Ther."},{"key":"219_CR21","doi-asserted-by":"crossref","unstructured":"Nazareth T, Datar M, Schwab P, et al. Relapse resolution and HCRU in patients with multiple sclerosis: a retrospective study of relapse therapy alternatives to corticosteroids [ECTRIMS-ACTRIMS poster EP1425]. ECTRIMS Online Library. 2017.","DOI":"10.26226\/morressier.59a3e8b5d462b8028d89464e"},{"issue":"8","key":"219_CR22","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1007\/s12325-016-0363-0","volume":"33","author":"LS Gold","year":"2016","unstructured":"Gold LS, Suh K, Schepman PB, et al. Healthcare costs and resource utilization in patients with multiple sclerosis relapses treated with H.P. Acthar Gel(\u00ae). Adv Ther. 2016;33(8):1279\u201392. https:\/\/doi.org\/10.1007\/s12325-016-0363-0.","journal-title":"Adv Ther."},{"key":"219_CR23","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2147\/dnnd.S208815","volume":"9","author":"J Costello","year":"2019","unstructured":"Costello J, Njue A, Lyall M, et al. Efficacy, safety, and quality-of-life of treatments for acute relapses of multiple sclerosis: results from a literature review of randomized controlled trials. Degener Neurol Neuromuscul Dis. 2019;9:55\u201378. https:\/\/doi.org\/10.2147\/dnnd.S208815.","journal-title":"Degener Neurol Neuromuscul Dis."},{"issue":"4","key":"219_CR24","doi-asserted-by":"publisher","first-page":"618","DOI":"10.3111\/13696998.2010.523670","volume":"13","author":"BJ Chastek","year":"2010","unstructured":"Chastek BJ, Oleen-Burkey M, Lopez-Bresnahan MV. Medical chart validation of an algorithm for identifying multiple sclerosis relapse in healthcare claims. J Med Econ. 2010;13(4):618\u201325. https:\/\/doi.org\/10.3111\/13696998.2010.523670.","journal-title":"J Med Econ."},{"issue":"6","key":"219_CR25","doi-asserted-by":"publisher","first-page":"469","DOI":"10.18553\/jmcp.2002.8.6.469","volume":"8","author":"DA Ollendorf","year":"2002","unstructured":"Ollendorf DA, Jilinskaia E, Oleen-Burkey M. Clinical and economic impact of glatiramer acetate versus beta interferon therapy among patients with multiple sclerosis in a managed care population. JMCP. 2002;8(6):469\u201376. https:\/\/doi.org\/10.18553\/jmcp.2002.8.6.469.","journal-title":"JMCP."},{"issue":"3","key":"219_CR26","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","volume":"46","author":"PC Austin","year":"2011","unstructured":"Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivar Behav Res. 2011;46(3):399\u2013424. https:\/\/doi.org\/10.1080\/00273171.2011.568786.","journal-title":"Multivar Behav Res"},{"issue":"11","key":"219_CR27","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","volume":"43","author":"H Quan","year":"2005","unstructured":"Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130\u20139. https:\/\/doi.org\/10.1097\/01.mlr.0000182534.19832.83.","journal-title":"Med Care"},{"key":"219_CR28","unstructured":"Pyenson B, Tomicki S. Multiple sclerosis: new perspectives on the patient journey: Milliman Client Report; 2019 [cited 2020 June 19]. https:\/\/us.milliman.com\/en\/insight\/multiple-sclerosis-new-perspectives-on-the-patient-journey-2019-update."},{"issue":"11","key":"219_CR29","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1212\/wnl.33.11.1444","volume":"33","author":"JF Kurtzke","year":"1983","unstructured":"Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33(11):1444\u201352. https:\/\/doi.org\/10.1212\/wnl.33.11.1444.","journal-title":"Neurology."},{"key":"219_CR30","unstructured":"Multiple Sclerosis Quality Measurement Set: American Academy of Neurology; 2014 [cited 2020 June 19]. https:\/\/www.aan.com\/siteassets\/home-page\/policy-and-guidelines\/quality\/quality-measures\/14msmeasureset_pg.pdf."},{"issue":"21","key":"219_CR31","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1212\/wnl.0000000000001965","volume":"85","author":"A Rae-Grant","year":"2015","unstructured":"Rae-Grant A, Bennett A, Sanders AE, et al. Quality improvement in neurology: multiple sclerosis quality measures: executive summary. Neurology. 2015;85(21):1904\u20138. https:\/\/doi.org\/10.1212\/wnl.0000000000001965.","journal-title":"Neurology."},{"issue":"4","key":"219_CR32","doi-asserted-by":"publisher","first-page":"202","DOI":"10.7224\/1537-2073.2014-097","volume":"18","author":"SJ Shoemaker","year":"2016","unstructured":"Shoemaker SJ, Pozniak A, Hadden L. Assessing four quality indicators for multiple sclerosis management through patient-reported data. Int J MS Care. 2016;18(4):202\u20139. https:\/\/doi.org\/10.7224\/1537-2073.2014-097.","journal-title":"Int J MS Care."}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-020-00219-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-020-00219-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-020-00219-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,21]],"date-time":"2021-05-21T15:23:20Z","timestamp":1621610600000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-020-00219-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,10]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["219"],"URL":"https:\/\/doi.org\/10.1007\/s40120-020-00219-y","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,10]]},"assertion":[{"value":"31 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}